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Abstract
Background: Estrogen is a pivotal regulator of cell proliferation in the normal breast and breast cancer. Endocrine therapies
targeting the estrogen receptor are effective in breast cancer, but their success is limited by intrinsic and acquired
resistance.
Methodology/Principal Findings: With the goal of gaining mechanistic insights into estrogen action and endocrine
resistance, we classified estrogen-regulated genes by function, and determined the relationship between functionally-
related genesets and the response to tamoxifen in breast cancer patients. Estrogen-responsive genes were identified by
transcript profiling of MCF-7 breast cancer cells. Pathway analysis based on functional annotation of these estrogen-
regulated genes identified gene signatures with known or predicted roles in cell cycle control, cell growth (i.e. ribosome
biogenesis and protein synthesis), cell death/survival signaling and transcriptional regulation. Since inducible expression of
c-Myc in antiestrogen-arrested cells can recapitulate many of the effects of estrogen on molecular endpoints related to cell
cycle progression, the estrogen-regulated genes that were also targets of c-Myc were identified using cells inducibly
expressing c-Myc. Selected genes classified as estrogen and c-Myc targets displayed similar levels of regulation by estrogen
and c-Myc and were not estrogen-regulated in the presence of siMyc. Genes regulated by c-Myc accounted for 50% of all
acutely estrogen-regulated genes but comprised 85% (110/129 genes) in the cell growth signature. siRNA-mediated
inhibition of c-Myc induction impaired estrogen regulation of ribosome biogenesis and protein synthesis, consistent with
the prediction that estrogen regulates cell growth principally via c-Myc. The ‘cell cycle’, ‘cell growth’ and ‘cell death’ gene
signatures each identified patients with an attenuated response in a cohort of 246 tamoxifen-treated patients. In
multivariate analysis the cell death signature was predictive independent of the cell cycle and cell growth signatures.
Conclusions/Significance: These functionally-based gene signatures can stratify patients treated with tamoxifen into
groups with differing outcome, and potentially identify distinct mechanisms of tamoxifen resistance.
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Introduction
Among several advances that have contributed to the decreased
mortality from breast cancer observed in the past decade, the
routine use of adjuvant endocrine therapies directed at the
estrogen-estrogen receptor (ER) pathway is a major contributor
[1,2]. Tamoxifen, which blocks estrogen action at its receptor,
increases survival following a diagnosis of breast cancer and
prevents the development of breast cancer in high risk women [1–
5]. The more recently-developed aromatase inhibitors, which
block estrogen synthesis, appear to be even more effective
therapies [6]. Thus, targeting the estrogen receptor pathway is a
validated, effective, biologically-based therapy for breast cancer.
However, the overall success of this therapeutic approach is
limited by both intrinsic and acquired resistance. A significant
proportion of patients with ER-positive tumors do not have
sustained objective responses, and many who do initially respond
subsequently relapse due to the acquisition of endocrine resistance
[7–9]. Prospective identification of patients who are not good
candidates for adjuvant endocrine therapy would substantially
facilitate clinical decision-making. To address this need, several
gene expression signatures that cosegregate with poor outcome in
PLoS ONE | www.plosone.org 1 August 2008 | Volume 3 | Issue 8 | e2987tamoxifen-treated breast cancer have been derived using gene
expression profiling, prospectively-selected candidate genes or
differentially-expressed estrogen-regulated genes [reviewed in 10].
A gene expression grade index (GGI) developed as a molecular
correlate of histological grade also cosegregates with poor response
to tamoxifen therapy [11]. There is little overlap between the
genes contained within these signatures, other than the frequent
inclusion of genes involved in cell proliferation, and thus although
potentially clinically useful, they offer limited insight into the
molecular basis of endocrine resistance.
The biochemical and molecular basis of antiestrogen (tamox-
ifen) resistance has been the subject of intense investigation.
Aberrations in ER expression and function, alterations in
coactivator and corepressor expression, ligand-independent acti-
vation of ER via growth factor-mediated phosphorylation events, a
switch from estrogen-driven cell-proliferation to EGFR/erbB2-
driven proliferation and the overexpression of various signaling
molecules, particularly the mitogen-activated protein kinases and
various isoforms of protein kinase C, have all been implicated in
endocrine resistance [7–9]. Consistent with the idea that
deregulation of estrogen target genes, particularly those that
mediate cell proliferation and survival, is another potential
mechanism of endocrine resistance, overexpression of the
estrogen-targeted cell cycle regulatory molecules c-Myc and cyclin
D1, which occurs at high frequency in the clinical setting, has been
associated with altered sensitivity to endocrine therapy [reviewed
in Ref. 12]. Inducible expression of these genes can over-ride
antiestrogen-induced growth arrest [13] and overexpression can
modulate sensitivity to clinically-relevant antiestrogens in in vitro
models [reviewed in Ref. 12].
Since estrogen is a multifunctional hormone, we reasoned that
the approach of seeking to identify a minimal gene set associated
with adverse outcome in tamoxifen-treated patients and the binary
nature of many of the resulting classifications might obscure some
of the complexity of the underlying biology. Furthermore, several
of the endocrine response signatures have been derived using
hierarchical clustering, which may not consistently result in stable
classification in independent sample sets [14]. With the goal of
gaining further mechanistic insights into estrogen action and
therefore into endocrine resistance, we sought to classify estrogen-
regulated genes by function, and then determine the impact of
deregulation of distinct functionally-related sets of genes on the
response to tamoxifen in breast cancer patients.
Results
Gene expression profiling and identification of estrogen-
regulated genes that are also c-Myc-regulated
Since inducible expression of c-Myc can overcome the
inhibitory effects of antiestrogens and recapitulate many of the
effects of estrogen on molecular endpoints related to cell cycle
progression [13] we reasoned that determining which estrogen-
regulated genes were also targets of c-Myc might provide insights
into the role of c-Myc in different aspects of estrogen action and in
antiestrogen resistance. To this end, a series of clonal MCF-7 cell
lines was developed that inducibly express c-Myc or c-Zip (a
deletion mutant of c-Myc that lacks the N-terminal transactivation
domains). Representative clones that had 17b-estradiol (E2) and
antiestrogen responses matched to those of the parental MCF-7
cells were chosen for further experiments (Fig. 1A&B). Zinc
treatment resulted in increased c-Myc or c-Zip expression within
3 h, similar to the timing of E2 induction of c-Myc (see Fig. 1D).
Induction of c-Myc led to re-initiation of cell cycle progression and
regulation of molecular endpoints that mimicked the effects of E2,
but induction of c-Zip was ineffective (Fig. 1). Cyclin D1 induction
preceded S phase entry in E2-treated cells, but was not apparent in
zinc-treated control or c-Myc transfected cells (Fig. 1D), consistent
with previous data obtained using this model system [13].
Using mitotically-selected cells, we previously established that
MCF-7 cell cycle progression is antiestrogen-sensitive in early-to-
mid G1 phase, but becomes independent of estrogen signaling 3–
4 h before S phase entry [15]. We therefore selected a timepoint
within the window of estrogen-dependent cell cycle progression,
6 h after estrogen treatment, and compared the gene expression
profile generated after estrogen treatment with that following zinc
induction of c-Myc or c-Zip. Initially, genes that were significantly
up- or down-regulated following E2 treatment compared with
vehicle-treated cells were identified (n=799 genes, represented by
939 probesets, adjusted p,0.01 i.e. false discovery rate 1%). The
estrogen-regulated genes were then divided into those that were
regulated in the same direction following c-Myc induction or E2
treatment but not regulated by c-Zip induction, designated ‘E2 and
Myc’ (adjusted p,0.01, 402/799 genes i.e. 50%), and the
remainder, designated ‘E2 not Myc’ (Fig. 2A, Table S1).
The relationship between the response to E2 treatment or c-Myc
induction for the 635 E2-upregulated probesets is shown in Fig. 2B.
Those in the ‘E2 and Myc’ category formed a cluster which was
largely distinct from the cluster designated ‘E2 not Myc’. At the
zinc concentration used for the microarray experiment, c-Myc
expression after zinc induction was higher than after estrogen
treatment, and consequently genes in the ‘E2 and Myc’ category
were more strongly regulated by c-Myc than by estrogen. The ‘E2
not Myc’ cluster included the most highly-regulated probes and
had an average relative expression of 0.97 after c-Myc induction.
In contrast, the distribution of downregulated probes in the ‘E2 not
Myc’ category essentially overlapped with that of the probes in the
‘E2 and Myc’ category (Fig. 2C). Databases of estrogen-responsive
genes [16] and c-Myc targets [17] were used to give an indication
of the proportion of the genes in each category that had been
previously identified as either estrogen- or c-Myc-regulated.
Almost 40% of the probes from the ‘E2 not Myc’ category that
increased in expression were previously-documented estrogen
targets (Fig. 2D), significantly more than the corresponding ‘E2
and Myc’ probes (P=9.86610
27, Fisher’s exact test). A similarly
high proportion of the probes in the ‘E2 and Myc’ category that
increased in expression were present in the Myc target gene
database (Fig. 2D), significantly more than in the ‘E2 not Myc’
category (P=1.64610
212), suggesting that this analysis identified
many bona fide c-Myc targets that have not been previously
described as estrogen targets. The presence of known c-Myc
targets in the ‘E2 not Myc’ categories might result, in part, from
misclassification, but likely also reflects cell-type specificity in the
response to c-Myc induction. For example, CCND1 (cyclin D1),
which is among the genes in the ‘E2 not Myc’ category, is present
in the c-Myc target gene database but does not increase after c-
Myc induction in this experimental model ([13], see also Fig. 1D).
If a c-Myc-dependent pathway is an integral part of the
response to estrogen, the changes in expression of targets in the ‘E2
and Myc’ category after estrogen treatment or zinc induction
would be expected to be of similar magnitude, provided similar
levels of c-Myc were achieved. To test this prediction, we adjusted
the concentration of zinc so that the induction of c-Myc mRNA
was similar to that after estrogen treatment (Fig. 3A), and
examined the expression of selected genes from the ‘E2 and
Myc’ category. The 5 genes examined all either increased
(HSU79274, HSPC 111, DKC1, MKI67IP), or decreased (CDKN1A,
encoding the CDK inhibitor p21
WAF1/Cip1) in expression to a
similar degree after E2 treatment or zinc induction of c-Myc
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PLoS ONE | www.plosone.org 2 August 2008 | Volume 3 | Issue 8 | e2987Figure 1. Effects of estrogen treatment and induction of c-Myc and c-Zip in antiestrogen-arrested cells. Cell lines stably transfected with
the inducible vector pDMT containing c-Myc, a c-Myc mutant lacking the entire N-terminal domain (c-Zip) or empty vector (Empty vector) were
growth arrested with 10 nM ICI 182780 for 48 h. Cells were treated at time zero with either 100 nM 17b-estradiol (E2) or vehicle (ethanol, EtOH) for
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PLoS ONE | www.plosone.org 3 August 2008 | Volume 3 | Issue 8 | e2987Figure 2. Comparison of genes regulated by estrogen and c-Myc. The experimental design is described in Fig. 1, except that a concentration
of 75 mM Zn was used. After 6 h E2 or Zn treatment, cells were harvested and transcript profiling undertaken using Affymetrix Human Genome U133
Plus 2.0 oligonucleotide microarrays. After normalisation and correction for multiple hypothesis testing, probesets that were significantly regulated in
the same direction by estrogen or c-Myc (but not by c-Zip) were identified (adjusted P,0.01). (A) The number of up-regulated (filled) or down-
regulated (hatched) genes classified as ‘E2 and Myc’ (red) or ‘E2 not Myc’ (blue) is shown. (B, C) The fold change in the expression of significantly-
regulated probesets following estrogen treatment (relative to vehicle (EtOH) treatment) is shown compared with that following zinc induction of c-
Myc (relative to zinc treatment of empty vector cells) as the average of three independent experiments. Red: ‘E2 and Myc’; Blue: ‘E2 not Myc’. (D) The
overlap between probesets in the indicated categories and publically available databases of estrogen-regulated genes (open bars) and c-Myc-
regulated genes (filled bars) is shown.
doi:10.1371/journal.pone.0002987.g002
the parental MCF-7, and 65 mM zinc for empty vector, c-Myc and c-Zip. (A, B) Cells additionally treated with nocodazole to prevent cell division of
estrogen-stimulated cells were harvested for analysis of cell cycle phase distribution by flow cytometry. A: Representative histograms 36 h after E2
and nocodazole treatment; B: mean6SD of 3 independent experiments. Control (EtOH): open bars; Zn (red) or E2 (blue). (C) The proportion of cells in
S phase was determined by flow cytometry at intervals after E2 or Zn treatment. Data are mean6SD of 3 independent experiments. E2, $ filled
circles; c-Myc, & filled squares; c-Zip, m filled triangles; EtOH, # open circles; Empty vector, h open squares. (D) Cell lysates were analysed by
immunoblotting for the proteins shown. Arrowhead indicates a non-specific protein (NS).
doi:10.1371/journal.pone.0002987.g001
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estrogen regulated via an estrogen-mediated increase in c-Myc
expression, MCF-7 human breast cancer cells were stimulated
with E2 in the presence of siRNAs directed at c-Myc (siMyc). The
most effective of the siRNAs tested, siMyc-17, reduced the
estrogen induction of c-Myc protein and mRNA at 6–9 h from
,5-fold to a statistically non-significant level of ,2-fold (Fig. 4A&B
and data not shown). In the presence of siMyc, none of the genes
Figure 3. Estrogen and c-Myc regulation of selected genes. The experimental design is described in Fig. 1. For the indicated genes, mRNA
levels were quantitated by qRT-PCR and are presented as the mean6range or SEM of 2–3 experiments. EtOH, E2, Empty and c-Myc data in (C) are
redrawn from [18].
doi:10.1371/journal.pone.0002987.g003
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MKI67IP), displayed significant induction after E2 treatment
(Fig. 4C–E). In contrast two genes from the ‘E2 not Myc’ category,
GREB1 and CCND1 (encoding cyclin D1), were both significantly
induced by E2 in either the presence or absence of siMyc
(Fig. 4F&G), despite evidence that CCND1 is a Myc target in other
systems. More detailed examination of the regulation of HSPC 111
showed that its induction by estrogen required ongoing protein
synthesis, did not occur in the presence of siMyc, and was
accompanied by recruitment of c-Myc to the HSPC 111 promoter
Figure 4. Effect of RNAi-mediated knockdown of c-Myc on regulation of selected genes after estrogen treatment. Cells were mock-
transfected or transfected with 50 nM of control (non-targetting siRNA, siNT2) or Myc siRNA (siMYC17), treated with antiestrogen (ICI 182780) for
48 h, and then treated with E2 for 6 h (A) or 9 h (B–G). (A) Protein lysates were immunoblotted for c-Myc 6 h after E2 treatment and quantitated by
densitometry. Data are the mean6range or SEM of 2–3 experiments. (B–G) For the indicated genes, mRNA levels were quantitated by qRT-PCR and
are presented as the mean6SEM of 3 experiments.
doi:10.1371/journal.pone.0002987.g004
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estrogen-mediated decreases in CDKN1A expression [19]. Thus,
estrogen regulation of all of these 5 genes from the ‘E2 and Myc’
category is dependent on c-Myc. Together these data provide
strong evidence that our analysis reliably distinguished genes
regulated by ‘E2 and Myc’ from those regulated by ‘E2 not Myc’,
and that genes in the ‘E2 and Myc ‘ category are regulated via
estrogen induction of c-Myc.
Pathway analysis of estrogen- and c-Myc-regulated
genes
In order to develop hypotheses about the biological processes
regulated by estrogen in this system we undertook further analysis
using the gene ontology tool Onto-Express [20] and Ingenuity
Pathways Analysis, which uses a curated database of known
functional interactions to identify networks of mammalian genes.
The entire set of estrogen-regulated genes, i.e. both ‘E2 and Myc’
and ‘E2 not Myc’, contained a significant over-representation of
genes in gene ontology biological process categories related to
ribosome biogenesis, the cell cycle and cell death (Table 1).
Ingenuity analysis of this geneset identified 4 networks with high
scores for relevance to the input dataset. These had the following
functional annotations: cancer, cell cycle, DNA replication, gene
expression and cell death. One network consisted of genes with
roles in the cell cycle and its gene signature was expanded by
including estrogen-regulated genes from gene ontology categories
related to the cell cycle and DNA replication (Fig. 5A, Table S2).
Ingenuity analysis of the ‘E2 not Myc’ signature identified one
high-scoring network that contained genes with roles in cell death
and substantially overlapped with two of the high-scoring networks
identified using the entire set of estrogen-regulated genes. The
main clusters of the latter networks were therefore combined, and
the resulting signature expanded by addition of genes from gene
ontology categories related to cell death (Fig. 5B, Table S2). The
fourth Ingenuity network derived from the entire estrogen-
regulated geneset, consisting of genes with roles in transcriptional
regulation, was not further modified (Fig. 5C, Table S2).
The functional annotation of the final gene signatures was
confirmed using Ingenuity (Table S3). The annotation of the ‘cell
cycle’ signature revealed a highly significant overrepresentation of
genes involved in: DNA replication and DNA metabolism, e.g.
several MCMs, PCNA, RFC2 and RFC4; cell cycle control, e.g.
CCND1 and CCNE2, encoding cyclins D1 and E2, respectively, and
CDKN1A, the gene encoding p21
Waf1/Cip1, which forms a central
node in this network; and cancer, including breast cancer. The ‘cell
death’ signature was annotated as containing genes involved in cell
death, apoptosis and survival. Cancer was also over-represented in
this network. Interestingly, for this signature the functional
annotations within cancer included invasion and migration as well
as cell death and general oncogenic processes (Table S3), and cell
movement was significantly overrepresented overall. The ‘tran-
scriptional regulation’ signature included a number of nuclear
receptor coregulators, and many of the genes have documented
functional interactions with the estrogen receptor (ESR1) (Fig. 5C).
The annotation of this network identified transcription and cancer
as significantly over-represented, as was development of the
mammary alveolus, albeit with a small number of genes (Table S3).
The gene ontology classifications of estrogen-regulated genes and
the processes represented by the Ingenuity networks displayed many
overlapping categories. However, several processes linked by their
importance in cell growth, i.e. the increase in cell mass that
accompanies progress through the cell cycle, were amongst those
mostsignificantly over-represented in the gene ontology (Table 1) but
were not well-represented in the Ingenuity networks, i.e. rRNA
processing, ribosome biogenesis and protein biosynthesis. This was
likely because much of the current understanding of these processes is
based on studies in model systems other than mammalian cells. We
therefore extended our analysis by predicting likely interactions using
theHumanInteractomeMap(HiMAP),whichbuildsnetworksbased
on known protein-protein interactions in human cells and on
Table 1. Gene ontology of all estrogen-regulated genes.
GO ID Function Name
Unique UniGene
Total
Unique Reference
UniGene Total
Corrected P-
Value
GO:0006364 rRNA processing 13 37 1.79E-09
GO:0007046 ribosome biogenesis 7 15 1.39E-08
GO:0008033 tRNA processing 9 37 2.69E-06
GO:0006412 protein biosynthesis 25 260 1.34E-04
GO:0006260 DNA replication 17 97 7.97E-07
GO:0006270 DNA replication initiation 6 19 1.75E-05
GO:0048015 phosphoinositide-mediated signaling 4 16 1.63E-03
GO:0006164 purine nucleotide biosynthesis 4 11 1.03E-03
GO:0009396 folic acid and derivative biosynthesis 3 7 1.66E-03
GO:0009113 purine base biosynthesis 3 4 2.58E-03
GO:0008285 negative regulation of cell proliferation 14 134 3.17E-03
GO:0000079 regulation of cyclin dependent protein kinase activity 5 35 6.36E-03
GO:0000074 regulation of cell cycle 18 213 7.49E-03
GO:0008632 apoptotic program 3 9 8.61E-03
GO:0007264 small GTPase mediated signal transduction 20 199 7.22E-04
GO:0042493 response to drug 3 15 9.18E-03
The analysis used Onto-Express, with a binomial distribution model and false discovery rate (FDR) correction for multiple comparisons. Only categories with 3 or more
genes are presented, and categories with related functions have been grouped together.
doi:10.1371/journal.pone.0002987.t001
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ordinate expression in a panel of human tissue samples, shared
biological function and conserved protein-protein interaction do-
mains [21]. A gene signature for ‘cell growth’ was compiled from an
initial small subnetwork identified by Ingenuity, together with genes
that were in relevant gene ontology categories or encoded proteins
that proteomic analysis has assigned to the nucleolus [22,23], and
estrogen-regulated genes that were predicted by HiMAP to have
direct connections to these genes. The network generated by HiMAP
from this list of genes was redrawn using Ingenuity (Fig. 5D) and
contained three major clusters that were largely composed of
predicted, rather than known, interactions. Using the gene ontology
classifications, data from proteomic analysis of the human ribosome
biogenesis pathway [23] and annotation of the final network using
Ingenuity, these clusters were identified as genes involved in protein
synthesis or RNA post-transcriptional modification, particularly
splicing, and components of the 90S pre-ribosomal complex (Tables
S2 & S3), consistent with the HiMAP prediction of functionally
relevant interactions between these genes.
To gain potential insights into the role of c-Myc in estrogen-
responsive biological processes, we determined what fraction of the
genes in each signature was regulated by c-Myc in our experimental
model (Fig. 5, Table S2). In total the ‘cell cycle’ gene signature
contained 60 genes, of which 27 (45%) were regulated by both
estrogen and c-Myc. Similarly, of the ‘transcriptional regulation’
signature 12 of 31 genes (39%) were regulated by c-Myc. The
proportion of genes in these two networks regulated by estrogen and
c-Myc was comparable with the 50% overall proportion (P=0.42
and 0.20, respectively, Fisher’s exact test). However, genes regulated
by both estrogen and c-Myc comprised only one-third of the total
genes in the ‘cell death’ network (19/55, i.e. 35%), significantly
different from the overall proportion (P=0.017). Conversely, the ‘cell
growth’ gene signature contained significantly more genes regulated
by c-Myc (102/123, 83%, P=5.5 610
216). These data suggest that
the degree to which estrogen regulation of cell cycle, cell growth and
cell death is secondary to the induction of c-Myc varies significantly.
Role of c-Myc induction in estrogen stimulation of cell
cycle progression and cell growth
Cell growth is necessary but not sufficient for S phase entry and
the two processes are closely co-ordinated [24]. Our pathway
analysis indicated that estrogen may regulate cell growth
principally via c-Myc. To test this prediction, we examined
whether estrogen regulated cell growth in this model system. The
first rate-limiting step in ribosome biogenesis is transcription of the
45S rRNA precursor, which is subsequently processed to yield
rRNAs that are integral to the ribosomal subunits. The 59
externally transcribed spacer (59ETS) of the 45S rRNA began to
increase in abundance 6–8 h after estrogen treatment (Fig. 6A),
significantly preceding the initiation of DNA synthesis, which was
first apparent after 12 h (Fig. 6B). Similarly, total protein synthesis
measured by [
35S]-methionine incorporation was increased by 6–
9 h after estrogen treatment (Fig. 6C). These endpoints were then
measured in antiestrogen-arrested MCF-7 human breast cancer
cells stimulated with E2 in the presence ofsiMyc-17, which reduced
the induction of c-Myc protein to less than 2-fold (Fig. 6D, see also
Fig. 4). Under these conditions, the increase in 59ETS levels was
inhibited, as was estrogen induction of total protein synthesis
(Fig. 6E). Thus, estrogen activates ribosome biogenesis and protein
synthesis in a c-Myc-dependent manner, as predicted by our
pathway analysis.
Relationship between functional signatures and
response to endocrine therapy
To determine whether the individual processes regulated by
estrogen might have different impacts on the response to
endocrine therapy, we examined the relationship between the
estrogen-regulated gene signatures and breast cancer patient
outcome using transcript profiles generated from a population of
246 women with ER-positive breast cancer who received
tamoxifen as their only adjuvant systemic therapy [11]. A semi-
supervised principal component method [25] was used to assess
the ability of each signature to predict time to development of
distant metastasis. The ‘cell cycle’, ‘cell death’ and ‘cell growth’
signatures were all prognostic (Table 2, Fig. 7A), but the
‘transcriptional regulation’ signature was not, although it con-
tained some genes that were individually significant predictors of
outcome (for example, CCND1 and NCOA1/SRC-1). MYC was not
prognostic as a continuous variable (P=0.372), and its inclusion in
either the cell cycle or cell growth signatures did not influence their
predictive ability. The three signatures that were significant
remained predictive in multivariate models against standard
clinicopathological parameters i.e. patient age, tumor grade,
tumor size and lymph node status, whether analysed using the
interquartile range (Table 3, models 1–3) or when treated as
continuous variables (Cell cycle P=0.001, HR 1.016, 95% CI
1.007–1.025; cell death P=0.0001, HR 1.022, 95% CI 1.011–
1.033; cell growth P=0.002, HR 1.015, 95% CI 1.005–1.024).
Since the ‘cell cycle’ and ‘cell growth’ signatures were strongly
correlated with tumor grade, grade was omitted from the models
for these signatures. To determine if the gene signatures gave
prognostic information additional to the clinical variables
described above, we generated a predictor based on a principal
components analysis using the clinical variables, and then
developed additional models using both the clinical variables
and the individual gene signatures. Using this alternative
approach, each signature still added significantly to the risk
prediction using the clinical covariates alone (Cell cycle P=0.002;
cell death P=0.05; cell growth P=0.04).
To gain possible insights into the contribution of components of
the processes represented by each signature, we further divided the
signatures. When the ‘cell growth’ signature was subdivided into
components representing RNA processing, ribosome biogenesis
and protein synthesis, each was individually prognostic (Table 2,
Fig. 7B). Because the ‘cell death’ signature contained some genes
that also had roles in processes that might be expected to affect
metastasis, i.e. cell migration and invasion, we assessed the
prognostic ability of genes with a ‘cell movement’ annotation
compared with the remainder of the signature. The ‘cell
movement’ subgroup was predictive (Table 2, Fig. 7C). However,
although for the remainder of the ‘cell death’ signature the high
risk and low risk groups diverged, this was not statistically
significant (Table 2, Fig. 7C).
The question of whether these signatures identified distinct
groups of patients is important in relation to both their potential
clinical utility and a better understanding of the underlying
Figure 5. Networks of estrogen-regulated genes. Gene ontology, Ingenuity Pathways analysis and HiMAP were used as detailed in the text to
generate networks of estrogen-regulated genes identified by transcript profiling after 6 h estrogen treatment of antiestrogen-arrested cells. Yellow:
‘E2 not Myc’; blue: ‘E2 and Myc’. Some genes were included for the purposes of illustration e.g. ESR1, encoding the ER, and are not coloured. A: cell
cycle; B: cell death; C: transcriptional regulation; D: cell growth.
doi:10.1371/journal.pone.0002987.g005
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PLoS ONE | www.plosone.org 9 August 2008 | Volume 3 | Issue 8 | e2987Figure 6. Effect of RNAi-mediated knockdown of c-Myc on cell growth after estrogen treatment. A, B: MCF-7 cells were growth arrested
with 10 nM ICI 182780 for 48 h then treated with either 100 nM E2 or vehicle (ethanol) (A) Abundance of the 59ETS of the 45S rRNA transcript was
measured using qRT-PCR. Vehicle control, # open circles; estrogen, $ filled circles. Data are mean6SEM of triplicate experiments. (B) Cells treated
with E2 for the indicated times were additionally treated with BrdU 2 h before harvesting. BrdU content (immunofluorescence) and DNA content
(propidium iodide staining) were measured using 2 parameter flow cytometry. (C) Overall protein synthesis was measured by [
35S]-methionine
incorporation at the indicated times after E2 treatment. Data are mean6range or SEM of 2–3 experiments. D, E: Cells were mock-transfected or
transfected with 100 nM of control (RISC-free, RF,) or Myc siRNAs (siMYC17), treated with antiestrogen (ICI 182780) for 48 h, and then treated with
100 nM E2 or vehicle (ethanol). (D) Protein lysates were immunoblotted for c-Myc. (E) 59ETS abundance (qRT-PCR) and protein synthesis ([
35S]-
methionine incorporation) were measured in the presence of control (RF) and c-Myc siRNAs (siMyc17) in duplicate experiments.
doi:10.1371/journal.pone.0002987.g006
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the cell cycle and cell growth signatures (r=0.653, p,0.01), but
weaker associations between cell cycle and cell death (r=0.326,
p,0.01), or cell growth and cell death (r=0.385, p,0.01).
Consistent with the idea that the cell death signature might
identify a distinct subset of patients, the discordance between
classification on the basis of the cell cycle or cell death signatures
was 42%, compared with 27% between the cell cycle and cell
growth signatures. Furthermore, patients classified as low risk
based on the ‘cell death’ signature, but not those classified as high
risk on this basis, could be separated into groups of differing
outcome on the basis of the ‘cell cycle’ signature (p=0.015 and
0.67, respectively; Fig. 7D). Finally, multivariate analysis compar-
ing all three signatures as continuous variables revealed that the
cell death signature was predictive independent of the other two
signatures whether analysed using the interquartile range (Table 3,
Model 4), or as continuous variables (Cell cycle P=0.058, HR
1.010, 95% CI 1.000–1.021; cell death P=0.009, HR 1.013, 95%
CI 1.003–1.023; cell growth P=0.287, HR 1.006, 95% CI 0.995–
1.017). In models including either ‘cell cycle’ or ‘cell growth’
against ‘cell death’ and the clinicopathological variables, all
remained predictive when analysed using the interquartile range
(Table 3, Models 5&6), although ‘cell growth’ did not when treated
as a continuous variable (Cell death vs cell cycle: cell cycle
P=0.006, HR 1.013, 95% CI 1.004–1.023; cell death P=0.038,
HR 1.010, 95% CI 1.001–1.020. Cell death vs. cell growth: cell
death P=0.005, HR 1.014, 95% CI 1.004–1.024; cell growth
P=0.081, HR 1.009, 95% CI 0.999–1.019). The ‘cell death’ and
‘cell cycle’ signatures therefore apparently confer independent
prognostic information.
Discussion
Estrogen action is necessary both for the normal development of
the female reproductive organs, including the mammary gland,
and for the development and proliferation of a majority of human
breast cancers. However, understanding the mechanisms under-
lying the physiological effects of this important hormone and how
their deregulation impacts on sensitivity to therapies directed at
the ER remains a significant challenge.
Role of c-Myc in estrogen action
By analysis based on functional annotation of acutely estrogen-
regulated genes we have identified gene signatures that encompass
four different aspects of estrogen action, and contain different
proportions of c-Myc-responsive genes: cell cycle control, cell
growth, cell death and transcriptional regulation. The proportion
of human protein-coding genes that is c-Myc-responsive is
estimated at 10–15% and many non-coding RNAs are also
regulated by c-Myc [26]. In addition, c-Myc and ERa binding
sites co-localise near the transcription start site of a subset of
estrogen-responsive genes [27]. Nonetheless, the observation that
as many as half of estrogen-responsive genes are also c-Myc-
responsive is striking and unexpected, and argues strongly for a
critical role for c-Myc in estrogen action. This was revealed by our
focus on the acute effects of E2 and use of an experimental model
designed to maximise sensitivity to the ability of E2 to promote the
G1-S phase transition, in contrast with previous analyses which
have often been undertaken over longer timeframes or in
experimental models with less sensitivity to effects on proliferation.
The different contributions of c-Myc-responsive genes to the
different estrogen-responsive signatures indicates that the role of c-
Myc may be specific to some processes, rather than global.
The ‘cell cycle’ network presented here integrates upstream cell
cycle regulatorymoleculeswith thosemoredirectly involved inDNA
replication i.e. PCNA, Cdc6, and the MCMs. Recent evidence that
c-Myc is associated with the pre-replication complex suggests one
means by which estrogen could regulate DNA replication [28].
However, c-Myc regulates the number of replication origins rather
than the rate of replication fork movement [28], while estrogen
increases the rate of replication fork movement [29]. Since many of
these DNA replication genes are E2F-responsive, estrogen stimula-
tion of E2F activity as cells progress through G1 phase [30,31]
provides a likely mechanism for their activation. Interestingly,
CDKN1A, the gene encoding p21
Waf1/Cip1, is a prominent hub
linking many of the genes within the ‘cell cycle’ signature, consistent
with studies identifying p21
Waf1/Cip1 as an important effector of c-
Myc action on the cell cycle in estrogen-treated cells [13,19]. Had
this not already been known, our analysis would have suggested
p21
Waf1/Cip1 as a strong candidate for further investigation,
highlighting the ability of these functional pathways to provide
mechanistic insights and suggesting that some of the hubs in other
networks merit further investigation as mediators of estrogen action.
Like the ‘cell cycle’ signature, the ‘transcriptional regulation’
signature contained approximately equal proportions of c-Myc-
regulated genes and genes unresponsive to c-Myc activation.
Prominent in the ‘transcriptional regulation’ network are a
number of nuclear receptor coregulators (the coactivators
NCOA1/SRC-1/RIP160, NCOA2/SRC-2/GRIP1, NCOA3/
AIB1/SRC-3, NCOA7, ARNT, ARNT2 and the corepressor
NRIP1/RP140), which play a central role in transcriptional
activation by members of the nuclear receptor superfamily [32]
and which were regulated in a manner consistent with the well-
known ligand-activated downregulation of estrogen receptor
signaling [33]. Interestingly, NCOA1, ARNT and ARNT2 and
one of two probsets for NCOA3 were also significantly
downregulated by c-Myc, suggesting that c-Myc-mediated repres-
sion may also contribute to this response.
Estrogen regulates both RNA and protein synthesis, an
important physiological response that was the focus of much early
work on estrogen action [34]. However, the molecular mecha-
nisms for estrogen effects on cell growth remain largely
unexplored. We show here that almost all of the acutely
estrogen-regulated genes with roles in cell growth are also c-Myc
targets, and that estrogen activation of rRNA synthesis and protein
synthesis depends on c-Myc. The idea that estrogen regulates cell
growth via c-Myc is supported by evidence that estrogen induction
of c-Myc in the rodent uterus is not prevented by progesterone,
Table 2. Analysis of functional signatures in tamoxifen-
treated patients.
Signature Log rank P
Cell cycle 0.036
Cell death 0.004
Cell movement 0.014
Remainder 0.076
Cell growth 0.01
RNA processing 0.03
Ribosome biogenesis 0.001
Protein synthesis 0.002
Transcriptional regulation 0.85
The log-rank p was generated after 500 permutations.
doi:10.1371/journal.pone.0002987.t002
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role of c-Myc in regulating cell growth in mammalian cells
[24,36].
Likethe ‘cellcycle’network,the‘celldeath’networkcontains both
effectors and upstream regulators. Bcl-2 acts as a hub connecting
many of the effectors, consistent with the well-documented role of
Figure 7. Relationship between estrogen-regulated gene signatures and response to tamoxifen therapy. Kaplan-Meier survival curves
of the relationship between time to distant metastasis and the indicated gene signatures, dichotomised at the 50th percentile, in a cohort of 246
breast cancer patients treated with tamoxifen. (A) Signatures illustrated in Fig. 5. (B) Subsets of the ‘cell growth’ signature. (C) Subsets of the ‘cell
death’ signature. (D) Patients were sequentially stratified using the ‘cell death’ and ‘cell cycle’ signatures.
doi:10.1371/journal.pone.0002987.g007
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The ‘cell death’ signature also contains components of survival
signaling pathways, e.g. receptor tyrosine kinases (IGF1R and Ret)
andtheireffectors(IRS1,Jak1,Jak2)thatareincreasedinresponseto
estrogen treatment. The implications of transcriptional regulation of
these signaling pathways has been much less well-studied than their
regulation by protein-protein interactions and phosphorylation, but
a co-ordinate increase in expression is likely to result in enhanced
survival signaling. Estrogen suppression of apoptosis resulting from
growth factor deprivation is c-Myc dependent [39] but genes
regulated by c-Myc were under-represented in the ‘cell death’
signature.However,ourexperimentalmodel,i.e.cellsculturedinthe
presence of serum and insulin, is rich in survival factors, and the
ability of estrogen to enhance survival signaling may further oppose
the ability of c-Myc to promote apoptosis in this model.
Deregulation of estrogen action and endocrine
resistance
An association between increased breast cancer proliferation
and poor outcome in response to endocrine therapies is clearly
apparent from studies measuring both individual markers of
proliferation (e.g. Ki67) and gene signatures associated with
reduced survival [10,40–42]. The particularly poor outcome of
highly proliferative ER-negative breast cancers and the association
between signatures containing prominent proliferation-related
components, for example the genomic grade signature [11], and
poor outcome in both untreated and tamoxifen-treated ER+ve
breast cancers [10], raises the question of whether increased
proliferation per se is a marker of an adverse prognosis, or whether
there are aspects of loss of proliferative control that affect response
to individual therapies. Whether the signatures identified here are
specifically predictive of response to tamoxifen or might also be
associated with poor response to other therapies remains to be
determined. However, in contrast with previous analyses in breast
cancer, we have distinguished cell cycle/cell growth, and cell
survival signatures that are independent predictors of outcome in
tamoxifen-treated patients.
A recent analysis of ‘molecular concepts’ associated with
progression of prostate cancer identified increased protein synthesis
and enrichment at chromosome 8q, which includes MYC (8q24), as
features distinguishing the precursor lesion prostatic intraepithelial
neoplasia (PIN) from benign epithelium [43]. The proliferation
signature was distinct from the protein synthesis network, and
although both increased during disease progression, they did so at
different stages [43], consistent with the idea that enhanced cell
cycle progression and enhanced cell growth may reflect different
initiating events. In our analysis c-Myc-responsive genes predom-
inated in the ‘cell growth’ signature, which contains many of the
most strongly c-Myc-regulated genes. The ‘cell growth’ signature
may therefore be a surrogate measure of deregulated c-Myc
expression that identifies a subset of proliferative, endocrine-
resistant breast cancers with distinct biology.
The poor outcome associated with the ‘cell growth’ signature
may reflect a specific resistance to endocrine therapies associated
with deregulation of c-Myc. However, the ‘wound signature’,
which is induced by co-ordinate amplification of MYC and CSN5/
JAB1/COPS5 [44], is predictive of a poor outcome in a cohort of
patients with ER-positive cancers who were more commonly
treated with chemotherapy than endocrine therapy [45], suggest-
ing that deregulation of c-Myc may result in resistance to multiple
therapies.
The well-established role of estrogen in promoting cell survival
suggests that increased apoptosis might be associated with a better
clinical response to endocrine therapies. However, clinical studies
addressing this question have often revealed conflicting data,
perhaps because of inherent difficulties in accurately monitoring
the dynamics of apoptosis in vivo [reviewed in 46]. As found by
another study identifying genes differentially expressed in
tamoxifen-sensitive and -insensitive breast cancer [47], the adverse
outcome predicted by the ‘cell death’ signature was associated with
both pro-apoptotic and anti-apoptotic changes in gene expression.
Consequently the likely effect of the observed changes in
expression within the ‘cell death’ signature is not clear. The dual
role of a subset of genes within the signature in regulating invasion
and motility provides another mechanism whereby their deregu-
lation may impair response to endocrine therapies. For example,
Bcl-2, which has functional interactions with many other genes
within the signature, has been implicated in estrogen regulation of
invasion downstream of RelB [48].
Table 3. Cox regression analysis.
Variable HR 95%CI P
Model 1
Cell cycle 4.028 1.816–8.937 0.001
Patient age 0.833 0.283–2.449 0.740
Tumor size 1.948 1.129–3.361 0.017
Nodal status 1.274 0.729–2.226 0.396
Model 2
Cell death 6.096 2.013–18.459 0.001
Patient age 0.902 0.267–3.049 0.868
Grade 1.011 0.636–1.608 0.962
Tumor size 1.988 1.059–3.734 0.033
Nodal status 1.323 0.718–2.439 0.370
Model 3
Growth 3.690 1.561–8.726 0.003
Patient age 0.959 0.333–2.761 0.937
Tumor size 1.875 1.081–3.252 0.025
Nodal status 1.411 0.819–2.432 0.215
Model 4
Cell cycle 2.401 0.993–5.804 0.052
Cell death 3.006 1.258–7.185 0.013
Cell growth 2.097 0.798–5.514 0.133
Model 5
Cell death 3.344 1.400–7.987 0.007
Cell cycle 2.785 1.203–6.446 0.038
Patient age 0.672 0.266–2.351 0.790
Tumor size 1.881 1.088–3.254 0.024
Nodal status 2.430 0.772–2.430 0.282
Model 6
Cell death 3.421 1.450–8.075 0.005
Cell growth 2.469 1.003–6.081 0.049
Patient age 0.876 0.299–2.564 0.809
Tumor size 1.846 1.062–3.210 0.030
Nodal status 1.429 0.821–2.489 0.207
For each signature the interquartile HR is shown i.e. highest vs. lowest quartile.
Grade is treated as a continuous variable (1 vs. 2 vs. 3) while tumor size (#2c m
vs. .2 cm), age (#50 vs. .50 yrs), and nodal status (negative vs. positive) are
binary variables.
doi:10.1371/journal.pone.0002987.t003
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predominance of c-Myc as a target of estrogen action, its specific
role as a mediator of estrogen effects on cell growth, and the ability
of functionally-based gene signatures to stratify patients treated
with tamoxifen into groups with differing outcome, potentially
identifying distinct mechanisms of tamoxifen resistance. This
provides an opportunity to identify new therapeutic options for
endocrine-resistant breast cancer.
Materials and Methods
Plasmid construction and transfection
The plasmids pDMT and pDMT-Myc, which contain a metal-
inducible metallothionein promoter [49] have been previously
described [13]. pDMT-c-Zip was constructed using the mouse c-
Zip cDNA subcloned from KS c-Zip [50]. MCF-7 cells were
transfected with either pDMT, pDMT-c-Myc or pDMT-c-Zip
together with a plasmid containing a selectable marker
(puromycin). Multiple individual puromycin-resistant colonies
(10–20 for each construct) were isolated, expanded and
characterised.
Cell culture, DNA flow cytometry and measurement of
protein synthesis
MCF-7 cells were maintained as previously described [51]. Stock
solutions of the pure antiestrogen ICI 182780 {7a-[9-(4,4,5,5-
pentafluoropentyl-sulfinyl)nonyl]estra-1,3,5(10)-triene-3,17b2diol}
and the steroid estradiol (17b-estradiol) were prepared as described
previously [52]. Stocks of Nocodazole {methyl-[5-(2-thienyl-
carbonyl)-1H-benzimidazol-2-yl] carbamate} were prepared in
DMSO and used at a final concentration of 50 ng/ml.
Exponentially proliferating cells were growth arrested by
pretreatment for 48 h with the steroidal antiestrogen ICI 182780
(10 nM) and then treated with either 100 nM E2 or 65 mM Zn (as
ZnSO4) as previously described [13]. DNA analysis by flow
cytometry was as previously described [13]. To measure protein
synthesis MCF-7 cells were labeled with 45 mCi [
35S]-methionine
for 20 mins as previously described [53].
Myc siRNA
siRNAs (siMyc-17 (D-003282-17-0050), non-targeting control 2
(D-001210-02-20) and RISC-Free siRNA (D-001220-01-20)) were
purchased from Dharmacon (Lafayette, Colorado, USA) and
transfected at 50 or 100 nM using Lipofectamine 2000 (Invitro-
gen). Transfection with fluorescinated siRNAs showed that .98%
of target cells were transfected. The siRNA/transfection mix was
removed 24 h after transfection and replaced with fresh RPMI
medium containing ICI 182780 (10 nM). After a further 48 h the
cells were treated with vehicle (ethanol) or E2 (17-b estradiol,
100 nM).
Western blot analysis
Cell lysates were prepared and immunoblotted as previously
described [52]. The following primary mouse monoclonal
antibodies were used: cyclin D1 (DSC-6, Novocastra, Laboratories
Ltd, Newcastle-upon-Tyne, UK), b-actin (AC-15, Sigma, St Louis,
MO, USA), p21 (610233; BD Transduction Laboratories,
Lexington, KY, USA), p27 (610241, BD Transduction Laborato-
ries, Lexington, KY, USA), pRB (554136, BD Pharmigen, San
Diego, CA, USA), c-Myc (9E10, Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA). The following primary rabbit polyclonal
antibodies were used: cyclin A (C-19), and c-Myc (C-19) (Santa
Cruz Biotechnology).
Quantitative Real-Time PCR
Total RNA was isolated using the RNAeasy kit (Qiagen) from
E2 or vehicle and Zn-treated cells and reverse-transcribed using
the Reverse Transcription System (Promega, NSW, Australia).
Real-time PCR was performed using an ABI Prism 7900HT
Sequence Detection System using inventoried Taq-Man probes
(Applied Biosystems, Foster City, CA, USA). GAPDH and RPLPO
were used as internal controls.
Transcript profiling and microarray data analysis
RNA was collected in three independent experiments, each
including parental cells treated with E2 or ethanol, zinc-treated
pDMT-c-Myc cells, zinc-treated pDMT-c-Zip cells and zinc-
treated empty vector (pDMT) cells. Cells were arrested for 48 h
with 10 nM ICI 182780 and then treated for 6 h with either
100 nM E2 or ethanol vehicle, or 75 mM zinc for the stably
transfected cell lines. Target probes were prepared and hybridised
to Affymetrix Human Genome U133 Plus 2.0 oligonucleotide
microarrays (Millennium Science, Box Hill, Vic, Australia)
according to the manufacturer’s instructions. The microarray
data are available through the Gene Expression Omnibus (GEO)
database (accession number GSE11791).
Quality of the arrays was assessed using histograms of probe
intensity, RNA degradation plots and Affymetrix-style quality
control measures generated using functions within the affy and
simpleaffy package of Bioconductor [54]. The arrays showed similar
‘gamma’ shaped distributions of probeset intensities, and had
scaling factors of 0.995–2.048 units, confirming their high quality
and suitability for batch normalization. Normalization of the
arrays was performed using the RMA algorithm, as implemented
in the affy package of Bioconductor and using the default options
of RMA (with background correction, quantile normalization, and
log transformation).
After normalisation probesets with intensity .100 in any of the
experimental conditions were analysed using Bayesian linear
modelling in the limma package [55], with replicate and treatment
as fixed effects. Penalized t-statistics from these comparisons were
generated by Benjamini and Yekutieli adjustment for multiple-
hypothesis comparisons [56] using the multtest package and probes
displaying significant differential expression (adjusted p,0.01)
were identified and compared with databases of estrogen-
responsive genes ((ERGDB, http://research.i2r.a-star.edu.sg/
promoter/Ergdb-v11/, [16]), c-Myc targets (http://www.
myc-cancer-gene.org, [17]), and nucleolar proteins (http://www.
lamondlab.com/NOPdb/, [22] current in November 2005.
Pathway analysis used Onto-Express (http://vortex.cs.wayne.
edu/index.htm, [20]), Ingenuity Pathways Analysis (Ingenuity
Systems, Redwood City, CA, http://www.ingenuity.com), and
HiMAP (www.himap.org [21]. Gene ontology and functional
annotation is presented for only those categories containing $3
genes and with an adjusted P value ,0.01.
Clinical microarray data
The clinical dataset used for analyzing the relationship between
the functional gene signatures and response to endocrine therapy
consisted of 246 primary breast cancer samples. The demograph-
ics and methods have been previously described [11] and the raw
data are available at the GEO database (accession number
GSE6532). All samples were required to be estrogen and/or
progesterone receptor positive by ligand-binding assay and had
received tamoxifen monotherapy only in the adjuvant setting. The
cut-off value for classification of patients as ER-positive or -
negative was 10 fmol per mg protein. The primary endpoint used
for generating the classifiers was the first distant metastatic event as
Estrogen- and c-Myc Targets
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given at relapse.
Data analyses were performed using version 3.5 of BRB
ArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.html). The
survival analyses were performed using the ‘survival risk prediction
tool’ where the survival risk groups are constructed using a
supervised principal component method [25]. All genes from each
of the functional networks that were present on the U133A
Affymetrix microarrays used for analysis of gene expression in
tamoxifen-treated patients were entered to generate the classifier.
Two principal components, 10-fold cross-validation and a binary
cut-off using the 50
th percentile were used to generate two
prognostic groups. The log-rank P value for the Kaplan-Meier
curve was generated after 500 permutations. To determine the
predictive accuracy of each of the functional gene signatures
compared with the clinical prognostic variables alone, two models
were created for each signature—one with clinical covariates only
and one with the clinical covariates and the gene signature. The
cross-validated Kaplan-Meier curves and log-rank statistics for
these models were generated after 500 permutations and the P
value measures whether the expression data significantly adds to
predictive accuracy compared with the clinical factors alone. This
approach is preferable to a multivariate model which only
compares prognostic effects and can be unstable due to multi-
colinearity between variables in the model and random fluctua-
tions in the data. Multivariate Cox regression analyses were
performed using SPSS statistical software package (SPSS Inc.
Chicago, IL) version 13.0. Each gene signature and tumor grade (1
vs. 2 vs. 3) were treated as continuous variables, while tumor size
(#2 cm vs. .2 cm), patient age (#50 vs. .50 yrs) and nodal
status (positive vs. negative) were treated as binary variables.
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